Botulinum neurotoxin in the treatment of headache disorders

Handbook of Clinical Neurology

Volumn 97, Issue C, 2010, Pages 217-232

  Mauskop, Alexander ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE BLIND PROCEDURE; HEADACHE; HEADACHE AND FACIAL PAIN; HUMAN; MIGRAINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; HEADACHE; HEADACHE DISORDERS; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77956287474     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(10)97017-6     Document Type: Book

References (74)

1. Aoki K.R. Botulinum toxin: a successful therapeutic protein. Curr Med Chem 2004, 11:3085-3092.
2. Aoki K.R. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 2005, 45:25-37.
3. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26:785-793.
4. Aoki K.R., Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001, 8(Suppl. 5):21-29.
5. Aurora S. Botulinum toxin type A for the treatment of migraine. Exp Opin Pharmacother 2006, 7:1085-1095.
6. Aurora S.K., Gawel M., Brandes J.L., et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2006, 47:486-499.
7. Aurora S.K., Gawel M., Brandes J.L., et al. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007, 47:486-499.
8. Aurora S.K., Schim J.D., Cutrer F.M., et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 1 trial double-blind phase. Cephalalgia 2009, 29(Suppl. 1):29.
9. Aurora S.K., Winner P., Freeman M.C., et al. Botulinum neurotoxin type A for treatment of chronic migraine: pooled analyses of the PREEMPT clinical program 32-week open-label phase. Cephalalgia 2009, 29(Suppl. 1):7.
10. Barrientos N., Chana P. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 2003, 4:146-151.
11. Binder W.J., Brin M.F., Blitzer A., et al. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000, 123:669-676.
12. Blumenfeld A., Chippendale T. Botulinum toxin type A compared with divalproex sodium for the prophylactic treatment of migraine: a randomized, evaluator-masked trial [poster] 2006.
13. Blumenfeld A., Binder W., Silberstein S.D., et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003, 43:884-891.
14. Blumenfeld A., Schim J., Chippendale T.J. Botulinum toxin type a and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008, 48:210-220.
15. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997, 20(Suppl. 6):S146-S168.
16. Conway S., Delplanche C., Crowder J., et al. Botox therapy for refractory chronic migraine. Headache 2005, 45:355-357.
17. Cui M., Khanijou S., Rubino J., et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-133.
18. de Paiva A., Meunier F.A., Molgó J., et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999, 96:3200-3205.
19. Dodick D.W., Mauskop A., Elkind A.H., et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005, 45:315-324.
20. Dodick D.W., Smith T.R., Becker W.J., et al. Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase. Cephalalgia 2009, 29(Suppl. 1):29.
21. Dodick D.W., Aurora S.K., Turkel C.C., et al. Botulinum neurotoxin type A for treatment of chronic migraine: the double-blind phase of the PREEMPT clinical program. Cephalalgia 2009, 29(Suppl. 1):34.
22. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003, 43(Suppl. 1):S16-S24.
23. Dressler D., Hallett M. Immunological aspects of Botox®, Dysport® and Myobloc™/neurobloc®. Eur J Urol 2006, 13(Suppl. 1):11-15.
24. Edwards K.R., Dreyer M.D. Botulinum toxin type A (Botox) for chronic daily headaches 2002.
25. Elkind A.H., O'Carrol P.O., Blumenfeld A., et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006, 10:688-696.
26. Eross E.J., Gladstone J.P., Lewis S., et al. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005, 45:308-314.
27. Evers S., Vollmer-Haase J., Schwaag S., et al. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 2004, 24:838-843.
28. Fadeyi M.O., Adams Q.M. Use of botulinum toxin type B for migraine and tension headaches. Am J Health Syst Pharm 2002, 59:1860-1862.
29. Freitag F.G., McAllister P., Freund B., et al. Botulinum toxin type A for the prophylaxis of chronic daily headache in migraineurs: effect on acute headache pain medication use [poster] 2005.
30. Freitag F.G., Diamond S., Diamond M., et al. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008, 48:201-209.
31. Freund B.J., Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache 2002, 42:1033-1037.
32. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994, 9:213-217.
33. Gwynn M.W., English J.B., Baker T.S. Double-blind, placebo-controlled study of Myobloc (botulinum toxin type B) for the treatment of chronic headache (abstract). Headache 2003, 43:577-578. (abstract S145).
34. Headache Classification Subcommittee of the International Headache Society The international classification of headache disorders, 2nd edn. Cephalalgia 2004, 24:1-160.
35. Huang W., Foster J.A., Rogachefsky A.S. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000, 43:249-259.
36. Jakubowski M., McAllister P., Bajwa Z., et al. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006, 125:286-295.
37. Jankovic J., Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995, 45:1743-1746.
38. Klapper J.A., Mathew N.T., Klapper A., et al. Botulinum toxin type A (BTX-A) for the prophylaxis of chronic daily headache. Cephalalgia 2000, 20:291-295.
39. Lake A.E., Saper J.R. Botulinum toxin type B for migraine prophylaxis: a 4-month open-label prospective outcome study. Headache 2003, 43:578. (abstract S146).
40. Lipton R.B., Varon S., Grosberg B., et al. Botulinum neurotoxin type A treatment improves health-related quality of life and reduces the impact of chronic migraine: results from the double-blind phase of the PREEMPT clinical program. Cephalalgia 2009, 29(Suppl. 1):32-33.
41. Mathew N.T., Kaup A.O. The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 2002, 4:365-373.
42. Mathew N.T., Stubits E., Nigam M.P. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982, 22:66-68.
43. Mathew N.T., Frishberg B.M., Gawel M., et al. Botulinum toxin type A (Botox®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005, 45:293-307.
44. Mauskop A. Long-term use of botulinum toxin type A (Botox) in the treatment of episodic and chronic migraine headaches [abstract] 2002.
45. Mauskop A. The use of botulinum toxin in the treatment of headaches. Pain Physician 2004, 7:377-387.
46. Mauskop A., Mathew N. Letter to the editor. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, Online, July 14, 2008.
47. McAllister P. Patient-reported improvement in headache and change in headache medication usage in a cohort treated with botulinum toxin type A (Botox). Headache 2003, 43:577. (abstract S143).
48. Meng J., Wang J., Lawrence G., et al. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007, 120:2864-2874.
49. Miller T., Denney L. Botulinum toxin A (Allergan) for chronic intractable headache; equally effective with or without concomitant neck pain. Headache 2003, 43:579. (abstract S148).
50. Naumann M., So Y., Argoff C.E., et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707-1714.
51. Ondo W.G., Vuong K.D., Derman H.S. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004, 24:60-65.
52. Opida C.L. Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches. Arch Pharmacol 2002, 365(Suppl. 2):R33. (abstract 97).
53. Opida C.L. Evaluation of Myobloc (botulinum toxin type B) in patients with post-whiplash headaches (abstract). Pain Med 2002, 3:178-179.
54. Padberg M., De Bruijn S.F., de Haan R.J., et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004, 24:675-680.
55. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of tension-type headache. Curr Rev Pain 2000, 4:31-35.
56. Relja M., Telarović S. Botulinum toxin in tension-type headache. J Neurol 2004, 251(Suppl. 1):I/12-I/14.
57. Relja M., Poole A.C., Schoenen J., et al. A multicenter, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2006, 27:492-503.
58. Rollnik J.D., Tanneberger O., Schubert M., et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000, 40:300-305.
59. Samton J., Mauskop A. Treatment of headache with botulinum toxin. Exp Rev Neurother 2006, 6:313-322.
60. Schmitt W.J., Slowey E., Fravi N., et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001, 41:658-664.
61. Schulte-Mattler W.J., Krack P. Treatment with chronic tension-type headache with botulinum toxin type A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004, 109:110-114.
62. Sebastian F.T., De Bruijn M. Treatment of chronic tension-type headache with botulinum toxin: a double-blind placebo controlled clinical trial. Neurology 2003, 60:148.
63. Shukla H.D., Sharma S.K. Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol 2005, 31:11-18.
64. Silberstein S.D., Stark S.R., Lucas S.M., et al. Botulinum toxin type a for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80:1126-1137.
65. Silberstein S.D., Gobel H., Jensen R., et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006, 26:790-800.
66. Silberstein S.D., Blumenfeld A.M., Cady R.K., et al. Botulinum neurotoxin type A for the treatment of chronic migraine: analysis of the PREEMPT chronic migraine subgroup with baseline acute headache medication overuse. Cephalalgia 2009, 29(Suppl. 1):31.
67. Silberstein S., Mathew N., Saper J., et al. Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445-450.
68. Smuts J.A., Baker M.K., Smuts H.M., et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 1999, 6(Suppl. 4):S99-S102.
69. Tepper S.J., Bigal M.E., Sheftell F.D., et al. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache 2004, 44:794-800.
70. Titner R., Gross R., Winzer U.F., et al. Autonomic function after botulinum toxin type A or B: a double blind, randomized trial. Neurology 2005, 65:765-767.
71. Troost B. Botulinum toxin type A (Botox®) therapy for intractable headache 2002.
72. Troost T., Rosenberg J.R., Wiles R. Improvement in intractable headache with repeated botulinum toxin type A treatment. Poster PO4.153. Neurology 2003, 60(Suppl. 1):A323-A324.
73. Wang J., Meng J., Lawrence G.W., et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem 2008, 283:16993-17002.
74. Yablon S.A., Daggett S., Lai F., et al. The development of toxin neutralizing antibodies with botulinum toxin type A (BoNTA) treatment [poster] 2006.